DE60236605D1 - Zusammensetzungen und deren verwendung zur behandlung von krebs - Google Patents

Zusammensetzungen und deren verwendung zur behandlung von krebs

Info

Publication number
DE60236605D1
DE60236605D1 DE60236605T DE60236605T DE60236605D1 DE 60236605 D1 DE60236605 D1 DE 60236605D1 DE 60236605 T DE60236605 T DE 60236605T DE 60236605 T DE60236605 T DE 60236605T DE 60236605 D1 DE60236605 D1 DE 60236605D1
Authority
DE
Germany
Prior art keywords
compositions
cancer
treatment
tumorigenesis
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60236605T
Other languages
English (en)
Inventor
Cynthia C Bamdad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Application granted granted Critical
Publication of DE60236605D1 publication Critical patent/DE60236605D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60236605T 2001-09-05 2002-09-05 Zusammensetzungen und deren verwendung zur behandlung von krebs Expired - Lifetime DE60236605D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31730201P 2001-09-05 2001-09-05
US37673202P 2002-05-01 2002-05-01
PCT/US2002/028576 WO2003020279A2 (en) 2001-09-05 2002-09-05 Compositions and methods of treatment of cancer

Publications (1)

Publication Number Publication Date
DE60236605D1 true DE60236605D1 (de) 2010-07-15

Family

ID=26980879

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60236605T Expired - Lifetime DE60236605D1 (de) 2001-09-05 2002-09-05 Zusammensetzungen und deren verwendung zur behandlung von krebs

Country Status (7)

Country Link
US (4) US8349853B2 (de)
EP (4) EP2329822A1 (de)
JP (1) JP2005507876A (de)
AT (1) ATE469648T1 (de)
CA (1) CA2459583A1 (de)
DE (1) DE60236605D1 (de)
WO (1) WO2003020279A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
EP2322929B1 (de) * 2000-11-27 2016-04-06 Minerva Biotechnologies Corporation Diagnostika, Drogenscreening und Behandlung für Krebs
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
AU2003213092A1 (en) * 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
ES2361403T3 (es) 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
BR0309892A2 (pt) * 2002-05-09 2011-04-05 Cytokinetics Inc composto, composição, métodos para modular a atividade da cinesina de ksp, para inibir a ksp, e para o tratamento de uma doença proliferativa celular, e, uso de um composto
JP2005530785A (ja) * 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
US7038048B2 (en) * 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
EP1556357A4 (de) * 2002-06-14 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
US20040048853A1 (en) * 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
EP1558083A4 (de) * 2002-09-30 2008-04-16 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP2363410B1 (de) * 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation MUC1-Isoformen
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
EP1680420A4 (de) * 2003-11-07 2008-09-24 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
JP2007513154A (ja) * 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
UA92317C2 (ru) * 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
WO2009042815A1 (en) * 2007-09-25 2009-04-02 Minerva Biotechnologies Corp. Methods for treatment of cancer
MX2010007430A (es) * 2008-01-11 2010-12-21 Albany Molecular Res Inc Piridoindoles (1-azinona)-sustituidos como antagonistas de la hormona de concentracion melanina humana.
EP4083072A1 (de) 2008-10-06 2022-11-02 Minerva Biotechnologies Corporation Muc1*-antikörper
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
TWI671297B (zh) 2009-05-27 2019-09-11 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) * 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
AU2012326137B2 (en) 2011-10-17 2018-11-29 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104995518A (zh) * 2012-07-24 2015-10-21 米纳瓦生物技术公司 Nme变体物种表达和抑制
CN111388664A (zh) 2012-08-14 2020-07-10 米纳瓦生物技术公司 干细胞增强疗法
KR20210082547A (ko) * 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법
MX2016004340A (es) 2013-10-04 2016-08-08 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2019028171A1 (en) 2017-08-01 2019-02-07 Ptc Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46997A (en) * 1865-03-28 James m
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
DE2351724A1 (de) * 1972-10-28 1974-05-09 Yamanouchi Pharma Co Ltd Neue nitrosoharnstoff-derivate
ATE115558T1 (de) * 1990-03-12 1994-12-15 Yamanouchi Pharma Co Ltd Harnstoffderivate, deren herstellung sowie diese enthaltende pharmazeutische zusammensetzungen.
GB9205907D0 (en) 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
JPH07258224A (ja) 1994-03-24 1995-10-09 Dai Ichi Seiyaku Co Ltd 二環性化合物
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
FR2748026B1 (fr) 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US6214879B1 (en) * 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
WO2000034783A1 (en) 1998-12-08 2000-06-15 Smithkline Beecham Corporation Methods of screening for agonists and antagonists of the hdpxu17 receptor
JP2002535656A (ja) 1999-01-23 2002-10-22 ミナーヴァ・バイオテクノロジーズ・コーポレーション コロイド固定化種と非コロイド構造上の種との相互作用
CA2361013A1 (en) 1999-01-25 2000-07-27 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
AU5382200A (en) * 1999-06-15 2001-01-02 University Health Network Muc1 ligands
EP1216232B1 (de) 1999-08-27 2006-10-11 ChemoCentryx Inc Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion
US6319915B1 (en) * 1999-08-27 2001-11-20 Pfizer Inc. Benzazepine derivatives as inhibitors of hyperproliferation diseases
EP1516876A1 (de) 1999-09-16 2005-03-23 Curis, Inc. Vermittler von Igel Signalwegen, deren Zusammenstellungen und Verwendungen
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
NZ518480A (en) * 1999-10-27 2004-02-27 Cytokinetics Inc Methods and compositions utilizing quinazolinones
US6683108B1 (en) * 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
AU2001253597A1 (en) 2000-04-12 2001-10-30 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
EP2322929B1 (de) 2000-11-27 2016-04-06 Minerva Biotechnologies Corporation Diagnostika, Drogenscreening und Behandlung für Krebs
WO2002064590A2 (en) * 2001-02-12 2002-08-22 Lilly Icos Llc Carboline derivatives
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
CA2459584A1 (en) * 2001-09-05 2003-03-13 Cynthia C. Bamdad Compositions and use thereof in the treatment of cancer
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法

Also Published As

Publication number Publication date
JP2005507876A (ja) 2005-03-24
US20160324858A1 (en) 2016-11-10
WO2003020279A3 (en) 2003-10-23
US20030130293A1 (en) 2003-07-10
WO2003020279A2 (en) 2003-03-13
EP1425016A2 (de) 2004-06-09
EP2116248A1 (de) 2009-11-11
US20170246168A1 (en) 2017-08-31
US8349853B2 (en) 2013-01-08
EP2340838A1 (de) 2011-07-06
EP1425016B1 (de) 2010-06-02
CA2459583A1 (en) 2003-03-13
US9649312B2 (en) 2017-05-16
EP2329822A1 (de) 2011-06-08
US20130190495A1 (en) 2013-07-25
ATE469648T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
DE60236605D1 (de) Zusammensetzungen und deren verwendung zur behandlung von krebs
ATE496033T1 (de) Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
DE60042693D1 (de) Dosierung für die behandlung mit anti erbb2-antikörpern
AU2003217055A1 (en) Protein for use in hypoxia related conditions
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
ATE455763T1 (de) Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit
DE602006010991D1 (de) 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
CY1110742T1 (el) Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης
ATE292974T1 (de) Arsentrioxidfreie arsensulfidverbindungen zur behandlung von hämatologischen tumoren
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
NO20060466L (no) Variable antibodies
DK0842934T3 (da) 5-HT1F agonister
DE602007010447D1 (de) Verwendung von 4,17-beta-dihydroxyandrost-4-en-3-on zur behandlung von krebs
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
DE60324544D1 (de) Muskarin antagonisten
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
ATE504293T1 (de) Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
BRPI0411085A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de vìrus oncogênicos, e de condições ou distúrbios devidos a infecção por hpv
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ID25478A (id) Agonis 5-ht1f
BRPI0410026A (pt) derivados de 3-amino-croman quinolina